Consumer Medicine Information (CMI) summary
The
full CMI on the next page has more details. If you are worried about receiving this vaccine,
speak to your doctor or pharmacist.
This vaccine is new or being used differently. Please report side effects. See the
full CMI for further details.
1. Why am I being given COMIRNATY JN.1?
COMIRNATY JN.1 is a vaccine given to prevent coronavirus disease 2019 (COVID-19) caused
by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in adults, infants
and children from 6 months of age and older. COMIRNATY JN.1 contains the active ingredient
bretovameran. For more information, see Section
1. Why am I being given COMIRNATY JN.1? in the full CMI.
2. What should I know before I am given COMIRNATY JN.1?
You should not be given COMIRNATY JN.1 if you have had an allergic reaction to any
of the ingredients in the vaccine. See list at the end of the CMI. Check with your
doctor if you have had: a severe allergic reaction or breathing problems after any
other vaccine or after being given any other COMIRNATY COVID-19 vaccine in the past;
fainted following any needle injection; a severe illness or infection with high fever;
a weakened immune system or are on a medicine that affects your immune system; a bleeding
disorder, bruise easily or are on a blood thinning medicine. Talk to your doctor if
you have any other medical conditions, take any other medicines, or are pregnant or
plan to become pregnant or are breastfeeding. COMIRNATY JN.1 should not be given to
infants under 6 months of age. For more information, see Section
2. What should I know before I am given COMIRNATY JN.1? in the full CMI.
3. What if I am taking other medicines?
Tell your doctor or pharmacist if you are taking any other medicines, including any
medicines, vitamins or supplements that you buy without a prescription. Tell your
doctor or pharmacist if you have recently received any other vaccine. For more information,
see Section
3. What if I am taking other medicines? in the full CMI.
4. How will I be given COMIRNATY JN.1?
COMIRNATY JN.1 will be given as an injection into the muscle of your upper arm or
thigh by a doctor, nurse or pharmacist. For children and adults 5 years of age and
older, you will be given one dose followed by a second dose at least 21 days later
as the primary vaccination. For infants and children 6 months to less than 5 years
of age, a third dose will be given at least 8 weeks after the second dose as a part
of the primary vaccination. A doctor, nurse or pharmacist will observe you for at
least 15 minutes after being given the vaccine. You may receive additional dose(s)
at least 3 months after the previous dose. For more information, see Section
4. How will I be given COMIRNATY JN.1? in the full CMI.
5. What should I know while being given COMIRNATY JN.1?
|
Things you should know
|
If you receive one dose of COMIRNATY JN.1, you should continue to receive the same
vaccine to complete the primary vaccination schedule.
Additional dose(s) of COMIRNATY JN.1 may be given at least 3 months after the previous
dose for people 5 years of age and older.
You may not be protected against COVID-19 disease until at least seven days after
the last dose of your primary vaccination schedule. It is very important you complete
your primary vaccination.
|
|
Driving or using machines
|
Be careful before you drive or use any machines or tools until you know how COMIRNATY
JN.1 affects you. Some of the side effects of COMIRNATY JN.1 may temporarily affect
your ability to drive or use machines.
|
6. Are there any side effects?
Very common side effects of COMIRNATY include pain/swelling at injection site, tiredness,
headache, muscle pain, chills, joint pain and fever. For more information, including
what to do if you have any side effects, see Section
6. Are there any side effects? in the full CMI.
This vaccine is subject to additional monitoring. This will allow quick identification
of new safety information. You can help by reporting any side effects you may get.
You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems .
Active ingredient:
bretovameran
Full Consumer Medicine Information (CMI)
This leaflet provides important information about using COMIRNATY JN.1. You should also speak to your doctor or pharmacist if you would like further information
or if you have any concerns or questions about receiving COMIRNATY JN.1.
Where to find information in this leaflet:
1. Why am I being given COMIRNATY JN.1?
COMIRNATY JN.1 contains the active ingredient bretovameran.
COMIRNATY JN.1 is an mRNA (messenger ribonucleic acid) vaccine.
COMIRNATY JN.1 is a vaccine given to prevent COVID-19 disease caused by SARS-CoV-2
virus in adults, infants and children from 6 months of age and older.
COMIRNATY JN.1 works by triggering your immune system to produce antibodies and blood
cells that work against the virus, to protect against COVID-19 disease.
2. What should I know before I am given COMIRNATY JN.1?
Warnings
COMIRNATY JN.1 should not be given:
if you are allergic to bretovameran or any of the ingredients listed at the end of
this leaflet.
Check with your doctor if you have:
had a severe allergic reaction or breathing problems after any other vaccine or after
being given any other COMIRNATY COVID-19 vaccine in the past.
fainted following any needle injection.
a severe illness or infection with high fever. However, you can have your vaccination
if you have a mild fever or upper airway infection like a cold.
a weakened immune system, such as due to HIV infection or are on a medicine that affects
your immune system.
a bleeding disorder, bruise easily or are on a blood thinning medicine.
During treatment, you may be at risk of developing certain side effects. It is important
you understand these risks and how to monitor for them. See additional information
under Section
6. Are there any side effects?
Very rare cases of myocarditis (inflammation of the heart muscle) and pericarditis
(inflammation of the lining outside the heart) have been reported after vaccination
with COMIRNATY. The cases have mostly occurred within two weeks following vaccination,
more often after the second vaccination, and more often, but not always, in younger
men. There have been cases in women. Following vaccination, you should be alert to
signs of myocarditis and pericarditis, such as breathlessness, palpitations and chest
pain, and seek immediate medical attention should these occur. Sometimes the symptoms
of myocarditis and pericarditis may not be specific and could include tiredness, dizziness,
nausea and vomiting, abdominal pain, swelling, and cough.
You may develop a temporary, stress-related response associated with the process of
receiving your injection. This may include dizziness, fainting, sweating, increased
heart rate and/or anxiety. If you start to feel faint at any time during the process
of receiving your injection, let your doctor, nurse or pharmacist know and take actions
to avoid falling and injuring yourself, such as sitting or lying down.
As with any vaccine, COMIRNATY JN.1 may not fully protect all those who receive it
and it is not known how long you will be protected.
Pregnancy and breastfeeding
If you are pregnant or breast-feeding, think you may be pregnant or are planning to
have a baby, ask your doctor or pharmacist for advice before you receive this vaccine.
Children and adolescents
COMIRNATY JN.1 should not be given to infants under 6 months of age.
3. What if I am taking other medicines?
Tell your doctor or pharmacist if you are taking, have recently taken or might take
any other medicines, including any medicines, vitamins or supplements that you buy
without a prescription from your pharmacy, supermarket or health food shop.
Tell your doctor or pharmacist if you have recently received any other vaccine.
Check with your doctor or pharmacist if you are not sure about what medicines, vitamins
or supplements you are taking and if these affect, or are affected by, COMIRNATY JN.1.
4. How will I be given COMIRNATY JN.1?
COMIRNATY JN.1 will be given as an injection into the muscle of your upper arm or
thigh by a doctor, nurse or pharmacist.
For primary vaccination, you will be given two doses. One dose followed by a second
dose at least 21 days later. If you miss the second dose, ask your doctor for advice.
If you are immunocompromised, you may receive a third dose of the vaccine at least
28 days after the second dose as part of the primary vaccination.
For infants and children 6 months to less than 5 years of age, a third dose will be
given at least 8 weeks after the second dose to complete the primary vaccination.
A doctor, nurse or pharmacist will observe you for at least 15 minutes after being
given the vaccine.
Additional dose(s) of COMIRNATY JN.1 may be given at least 3 months after the primary
vaccination for people 5 years of age and older.
5. What should I know while being given COMIRNATY JN.1?
Things you should know
If you receive one dose of COMIRNATY JN.1, you should continue to receive the same
vaccine to complete the primary vaccination schedule.
If you are immunocompromised, you may receive a third dose of COMIRNATY JN.1 at least
28 days after the second dose as part of the primary vaccination.
Additional dose(s) of COMIRNATY JN.1 may be given at least 3 months after the previous
dose for people 5 years of age and older.
You may not be protected against COVID-19 disease until at least seven days after
primary vaccination.
You may not be protected if you only receive one dose, so it is very important that
you complete your primary vaccination.
Driving or using machines
Be careful before you drive, cycle or use any machines or tools until you know how
COMIRNATY JN.1 affects you.
Some of the side effects of COMIRNATY JN.1 may temporarily affect your ability to
drive, cycle or use machines.
Storage of the vaccine
A doctor, nurse or pharmacist will prepare the injection for you before you are given
it.
Getting rid of any unwanted vaccine
A doctor, nurse or pharmacist will dispose of any unused vaccine.
6. Are there any side effects?
All medicines can have side effects. If you do experience any side effects, most of
them are minor and temporary. However, some side effects may need medical attention.
See the information below and, if you need to, ask your doctor or pharmacist if you
have any further questions about side effects.
Very common side effects
Common side effects
Uncommon side effects
Rare side effects
Other side effects (frequency unknown)
Tell your doctor or pharmacist if you notice anything else that may be making you
feel unwell.
Other side effects not listed here may occur in some people.
Reporting side effects
After you have received medical advice for any side effects you experience, you can
report side effects to the Therapeutic Goods Administration online at
www.tga.gov.au/reporting-problems . By reporting side effects, you can help provide more information on the safety of
this vaccine.
7. Product details
What COMIRNATY JN.1 contains
|
Active ingredient
(main ingredient)
|
bretovameran
|
|
Other ingredients
(inactive ingredients)
|
((4-hydroxybutyl)azanediyl) bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315)
2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159)
Distearoylphosphatidylcholine (DSPC)
Cholesterol
Sucrose
Trometamol
Trometamol hydrochloride
Water for injections
|
Do not receive this vaccine if you are allergic to any of these ingredients.
What COMIRNATY JN.1 looks like
COMIRNATY JN.1 (Grey, Orange and Maroon cap) is a white to off-white frozen suspension.
COMIRNATY JN.1 (Blue and Yellow cap) is a clear to slightly opalescent solution. COMIRNATY
JN.1 – Single dose Glass Prefilled Syringes and Single dose Plastic Prefilled Syringes
is a white to off-white suspension.
Yellow cap vial (For Age 6 months to less than 5 Years):
COMIRNATY JN.1 (Yellow cap) is provided in packs of 10 and 195 in clear glass vials
with yellow flip-off caps. After dilution, each dose is 0.3 mL and each vial contains
3 doses of vaccine (0.48 mL fill). AUST R 457690
Maroon cap vial (For Age 6 months to less than 5 Years):
COMIRNATY JN.1 (Maroon cap) is provided in packs of 10 and 195 in clear glass vials
with maroon flip-off caps. After dilution, each dose is 0.2 mL and each vial contains
10 doses of vaccine (0.4 mL fill). AUST R 457688
Blue cap vial (For Age 5 to less than 12 Years):
COMIRNATY JN.1 (Light or Dark Blue cap) is provided in packs of 10 in clear glass
vials with blue flip-off caps. No dilution required. Each dose is 0.3 mL.
Each single dose vial (Light Blue) contains 1 dose of vaccine (0.48 mL fill). AUST
R 457686
Each multidose vial (Dark Blue) contains 6 doses of vaccine (2.25 mL fill). AUST R
457685
Orange cap vial (For Age 5 to less than 12 Years):
COMIRNATY JN.1 (Orange cap) is provided in packs of 10 and 195 in clear glass vials
with orange flip-off caps. After dilution, each dose is 0.2 mL and each vial contains
10 doses of vaccine (1.3 mL fill). AUST R 457680
Grey cap vial (For Ages 12 Years and older):
COMIRNATY JN.1 (Light or Dark Grey cap) is provided in packs of 10 in clear glass
vials with grey flip-off caps. No dilution required. Each dose is 0.3 mL.
Each single dose vial (Light Grey) contains 1 dose of vaccine (0.48 mL fill). AUST
R 457679
Each multidose vial (Dark Grey) contains 6 doses of vaccine (2.25 mL fill). AUST R
457677
Single dose Glass Prefilled Syringes (For Ages 12 Years and older):
COMIRNATY JN.1 – Single dose Glass Prefilled Syringes is provided in packs of 10 in
clear glass syringes with a rigid cap. No dilution is required. Each dose is 0.3 mL.
Each single dose glass syringe contains 1 dose of vaccine (0.418 mL fill). AUST R
459385
Single dose Plastic Prefilled Syringes (For Ages 12 Years and older):
COMIRNATY JN.1 – Single dose Plastic Prefilled Syringes is provided in packs of 10
in transparent plastic syringes with a rigid cap. No dilution is required. Each dose
is 0.3 mL.
Each single dose plastic syringe contains 1 dose of vaccine (0.432 mL fill). AUST
R 459366
Not all presentations may be available.
Who distributes COMIRNATY JN.1
Pfizer Australia Pty Ltd
Sydney NSW
Toll Free Number: 1800 675 229
COMIRNATY® is a registered trademark of BioNTech SE. Used under license.
This leaflet was prepared in October 2024.
© Copyright